Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allergovac Hymenoptera is a subcutaneous venom immunotherapy product containing standardized Hymenoptera venoms (typically honey bee Apis mellifera and vespid species such as Vespula spp. and Polistes dominula) used for desensitization of patients with IgE-mediated hymenoptera venom allergy who are at risk of systemic anaphylactic reactions to stings. The preparation consists of purified venom extracts formulated for gradual up‑dosing to a maintenance dose (usually around 100 µg of venom) in order to shift the immune response from an IgE‑mediated, mast cell–activating profile toward a more tolerogenic, IgG4‑dominated and T‑regulatory cell–associated response, thereby markedly reducing the risk and severity of systemic reactions upon subsequent natural stings.[1][3][9][11][12]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Allergovac Hymenoptera.